Table 2

Prespecified and post hoc efficacy analyses.

STX209 (least squares
mean ± SEM), n = 60*
Placebo (least squares
mean ± SEM), n = 62*
P
BaselineEnd of treatmentBaselineEnd of treatment
Prespecified analyses
  ABC-I21.0 ± 1.1416.4 ± 0.9521.8 ± 1.2916.2 ± 0.950.89
  CGI-I3.1 ± 0.163.5 ± 0.160.15
  CGI-S5.1 ± 0.134.5 ± 0.125.1 ± 0.144.8 ± 0.120.09
  Blinded treatment preference (clinician)26 (57%)13 (28%)0.05
  Blinded treatment preference (parent)27 (59%)15 (33%)0.09
  VAS problem behaviors2.2 ± 0.224.2 ± 0.321.9 ± 0.203.1 ± 0.330.04
Post hoc analysis
  ABC—Social Avoidance4.5 ± 0.463.3 ± 0.443.9 ± 0.433.6 ± 0.410.008

*Numbers reflect n for analysis of ABC-I. n differs slightly for other variables because of missing data.